Expression of Lewis y antigen and integrin αv, β3 in ovarian cancer and their relationship with chemotherapeutic drug resistance
Open Access
- 1 June 2013
- journal article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1) , 36
Abstract
This study investigates the expression of Lewis y antigen, integrin αv, β3 in epithelial ovarian cancer tissues. We further evaluate the relationship between their expression and chemotherapy resistance of ovarian cancer and its possible clinical significance. Tissues of 92 patients with ovarian cancer meeting the inclusion criteria with complete follow-up data were enrolled and divided into chemotherapy resistant group and sensitive group. The expression and relationship of Lewis y antigen and integrin αv, β3 are assessed in paraffin sections using immunohistochemistry and double-labeling immunofluorescence method. Multivariate logistic regression analysis was used to investigate the relationship between age, clinical stage, differentiation, histologic subtype, Lewis y antigen and integrin αv, β3 expression in ovarian cancer patients. The expression rates of Lewis y antigen and integrin αv in the resistant group, significantly higher than the rates found in the sensitive group (p <0.05). Multivariate analysis showed that the expression of Lewis y antigen, integrin αv and ovarian cancer's clinical stage were independent, drug resistance-related risk factors. The expression levels of Lewis y antigen and integrin αv, β3 were positively correlated with each other. A close correlation between Lewis y antigen, integrin αv, β3 and ovarian cancer was observed. Lewis y antigen can influence the biological behavior of a tumor cell as an important composition of integrin αv, β3 by some signal pathway. And the expression of Lewis y antigen, integrin αv and ovarian cancer's clinical stage are both independent, drug resistance-related risk factors.Keywords
This publication has 20 references indexed in Scilit:
- Increase in Docetaxel-Resistance of Ovarian Carcinoma-Derived RMG-1 Cells with Enhanced Expression of Lewis Y AntigenInternational Journal of Molecular Sciences, 2011
- Study on the Expression and Clinical Significances of Lewis y Antigen and Integrin αv, β3 in Epithelial Ovarian TumorsInternational Journal of Molecular Sciences, 2011
- Overexpression of Lewis (y) Antigen Protects Ovarian Cancer RMG‐1 Cells from Carboplatin‐Induced Apoptosis by the Upregulation of Topo‐I and Topo‐II βThe Anatomical Record, 2011
- Enhancive effects of Lewis y antigen on CD44-mediated adhesion and spreading of human ovarian cancer cell line RMG-IJournal of Experimental & Clinical Cancer Research, 2011
- Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin α5β1 with the Lewis Y-structure on transfection of the α1,2-fucosyltransferase geneBiochimie, 2010
- Alterations in the glycolipid composition and cellular properties of ovarian carcinoma‐derived RMG‐1 cells on transfection of the α1,2‐fucosyltransferase geneCancer Science, 2005
- Integrin β4 signaling promotes tumor angiogenesisCancer Cell, 2004
- Altered adhesion properties and alpha v integrin expression in a cisplatin‐resistant human ovarian carcinoma cell lineInternational Journal of Cancer, 2001
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997